Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Analytical techniques for boron and boron 10 analysis in a solid experimental tumor EO. 771.

W Porschen1, J Marx, F Dallacker

  • 1Institut für Medizin, Kernforschungsanlage GmbH, Jülich, Federal Republic of Germany.

Radiation and Environmental Biophysics
|January 1, 1987
PubMed
Summary

A new boron-10 glycineamide analog (A8) shows promise for boron neutron capture therapy. Intratumoral A8 combined with thermal neutrons significantly delayed tumor growth and altered cell cycles in mice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of detergent-based cleaning and wiping against SARS-CoV-2 on high-touch surfaces.

Letters in applied microbiology·2023
Same author

Peritoneal carcinomatosis of colorectal origin treated by cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy at the Bulovka University Hospital.

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2022
Same author

Erratum: Azimuthal Anisotropy of K_{S}^{0} and Λ+Λ[over ¯] Production at Midrapidity from Au+Au Collisions at sqrt[s]_{NN}=130  GeV [Phys. Rev. Lett. 89, 132301 (2002)].

Physical review letters·2021
Same author

Erratum: Azimuthal Anisotropy at the Relativistic Heavy Ion Collider: The First and Fourth Harmonics [Phys. Rev. Lett. 92, 062301 (2004)].

Physical review letters·2021
Same author

Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2020
Same author

Perspectives on expedited partner therapy for chlamydia: a survey of health care providers.

International journal of STD & AIDS·2015

Area of Science:

  • Oncology
  • Radiochemistry
  • Medical Physics

Background:

  • Boron Neutron Capture Therapy (BNCT) targets tumors using boron-10 compounds and thermal neutrons.
  • Previous BNCT agents include trimethylamine-carboxyborane (A3) and amine-carboxyborane (A7).
  • A novel boron-10 glycineamide analog, amineboryl-carboxamide (A8), has been synthesized.

Purpose of the Study:

  • To synthesize and evaluate the efficacy of the new boron-10 glycineamide analog (A8) for BNCT.
  • To assess the therapeutic effects of A8 on solid adenocarcinoma EO 771 in mice.
  • To analyze boron distribution, tumor growth delay, and cell cycle changes.

Main Methods:

  • Synthesis of boron-10 glycineamide analog (A8) with 13.81% boron content.
  • Testing A8 efficacy in syngeneic solid adenocarcinoma EO 771 in C57 BL/6J mice.

Related Experiment Videos

  • Boron distribution analysis using ICP emission spectroscopy.
  • Tumor boron-10 concentration analysis via prompt gamma-activation and neutron capture radiography.
  • Flow cytometry to evaluate cell cycle changes.

    • Main Results:

    • A8 demonstrated very low toxicity in mice.
    • A8 alone or thermal neutron irradiation alone resulted in 1-2 days of tumor growth delay.
    • Intraperitoneal A8 with neutrons yielded a 3-6 day growth delay.
    • Intratumoral A8 with neutrons achieved a 7-14 day growth delay.
    • Flow cytometry showed an increase in (G2 + M) phase cells from 35% to 52% with combined treatment.

    Conclusions:

    • The boron-10 glycineamide analog (A8) is a promising candidate for BNCT due to its low toxicity and significant tumor growth inhibition.
    • Intratumoral delivery of A8 combined with thermal neutron irradiation is more effective than systemic delivery.
    • A8 treatment alters tumor cell cycle progression, contributing to therapeutic efficacy.